RU2702163C2 - Вакцины против малярии - Google Patents

Вакцины против малярии Download PDF

Info

Publication number
RU2702163C2
RU2702163C2 RU2015155821A RU2015155821A RU2702163C2 RU 2702163 C2 RU2702163 C2 RU 2702163C2 RU 2015155821 A RU2015155821 A RU 2015155821A RU 2015155821 A RU2015155821 A RU 2015155821A RU 2702163 C2 RU2702163 C2 RU 2702163C2
Authority
RU
Russia
Prior art keywords
virus
antigen
malaria
seq
polypeptide
Prior art date
Application number
RU2015155821A
Other languages
English (en)
Russian (ru)
Other versions
RU2015155821A3 (cg-RX-API-DMAC7.html
RU2015155821A (ru
Inventor
Рюдзи УЭНО
Ватару АКАХАТА
Original Assignee
Влп Терапьютикс, Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Влп Терапьютикс, Ллк filed Critical Влп Терапьютикс, Ллк
Publication of RU2015155821A publication Critical patent/RU2015155821A/ru
Publication of RU2015155821A3 publication Critical patent/RU2015155821A3/ru
Application granted granted Critical
Publication of RU2702163C2 publication Critical patent/RU2702163C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/193—Equine encephalomyelitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015155821A 2013-06-03 2014-06-02 Вакцины против малярии RU2702163C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361830436P 2013-06-03 2013-06-03
US61/830,436 2013-06-03
US201361906583P 2013-11-20 2013-11-20
US61/906,583 2013-11-20
PCT/JP2014/065166 WO2014196648A1 (en) 2013-06-03 2014-06-02 Malaria vaccine

Publications (3)

Publication Number Publication Date
RU2015155821A RU2015155821A (ru) 2017-06-29
RU2015155821A3 RU2015155821A3 (cg-RX-API-DMAC7.html) 2018-06-05
RU2702163C2 true RU2702163C2 (ru) 2019-10-04

Family

ID=52005658

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015155821A RU2702163C2 (ru) 2013-06-03 2014-06-02 Вакцины против малярии

Country Status (16)

Country Link
US (3) US9512190B2 (cg-RX-API-DMAC7.html)
EP (1) EP3004348B1 (cg-RX-API-DMAC7.html)
JP (1) JP6734651B2 (cg-RX-API-DMAC7.html)
KR (2) KR102494564B1 (cg-RX-API-DMAC7.html)
CN (1) CN105431535A (cg-RX-API-DMAC7.html)
AP (1) AP2015008926A0 (cg-RX-API-DMAC7.html)
AU (1) AU2014275772B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015030229B1 (cg-RX-API-DMAC7.html)
CA (1) CA2913832C (cg-RX-API-DMAC7.html)
IL (1) IL242656B (cg-RX-API-DMAC7.html)
MX (1) MX386234B (cg-RX-API-DMAC7.html)
RU (1) RU2702163C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201709917VA (cg-RX-API-DMAC7.html)
TW (1) TWI687442B (cg-RX-API-DMAC7.html)
WO (1) WO2014196648A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201508642B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013221187B9 (en) 2012-02-16 2018-01-04 Vlp Therapeutics, Inc. Virus like particle composition
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
WO2016021209A1 (en) 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
EP3191589B1 (en) 2014-09-11 2025-11-26 VLP Therapeutics, Inc. Flavivirus virus like particle
US10166281B2 (en) * 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
US9968665B2 (en) * 2015-09-16 2018-05-15 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
SG11201909265QA (en) 2017-04-19 2019-11-28 Inst Res Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
CN110612116A (zh) 2017-05-08 2019-12-24 磨石肿瘤生物技术公司 甲病毒新抗原载体
KR102823029B1 (ko) 2017-12-20 2025-06-20 브이엘피 테라퓨틱스 인코포레이티드 알파바이러스 레플리콘 입자
AU2019205330B2 (en) 2018-01-04 2025-09-11 Iconic Therapeutics Llc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
TW202523847A (zh) 2019-05-30 2025-06-16 美商磨石生物公司 經修飾之腺病毒
US12280102B2 (en) 2020-04-17 2025-04-22 Vlp Therapeutics, Inc. Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains
CN115552009A (zh) 2020-04-30 2022-12-30 Vlp治疗公司 细胞因子免疫疗法
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
CN118510792A (zh) * 2021-11-22 2024-08-16 诺瓦瓦克斯公司 用于治疗和预防疟疾的方法和组合物
WO2025064770A2 (en) * 2023-09-20 2025-03-27 La Jolla Institute of Immunology Alphavirus t cell epitopes, megapools and uses thereof
WO2025084276A1 (ja) * 2023-10-16 2025-04-24 Ｃｙｎ－Ｋバイオ株式会社 肥満の処置

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025067A1 (en) * 2006-08-30 2008-03-06 Hepgenics Pty Ltd Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
WO2011035004A1 (en) * 2009-09-18 2011-03-24 Fraunhofer Usa Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
WO2012006180A1 (en) * 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012106356A2 (en) * 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
RU2014133527A (ru) * 2012-02-16 2016-03-10 Влп Терапьютикс, Ллк Композиция вирусоподобных частиц

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100251505B1 (ko) * 1991-11-16 2000-05-01 장 스테판느 말라리아원충으로부터의 cs 및 hbsag 사이의 혼성 단백질(hybrid protein between cs from plasmodium and hbsag)
AU2003295470A1 (en) 2002-11-13 2004-06-03 The United States Of America As Represented By The Secretary Of The Navy Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
US20080131461A1 (en) * 2004-10-14 2008-06-05 Crucell Holland B.V. Malaria Prime/Boost Vaccines
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CN102317308A (zh) * 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
WO2012023995A1 (en) * 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
WO2016021209A1 (en) 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025067A1 (en) * 2006-08-30 2008-03-06 Hepgenics Pty Ltd Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
WO2011035004A1 (en) * 2009-09-18 2011-03-24 Fraunhofer Usa Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
WO2012006180A1 (en) * 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012106356A2 (en) * 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
RU2014133527A (ru) * 2012-02-16 2016-03-10 Влп Терапьютикс, Ллк Композиция вирусоподобных частиц

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AKAHATA W et al., A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection, Nat. Med., 2010, vol. 16, No. 3, pp. 334-338. *
AKAHATA W et al., A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection, Nat. Med., 2010, vol. 16, No. 3, pp. 334-338. Birkett et al. A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of the Plasmodium falciparum Circumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts. INFECTION AND IMMUNITY, Dec. 2002, vol. 70, No. 12, p. 6860-6870. Б. ГЛИК. МОЛЕКУЛЯРНАЯ БИОТЕХНОЛОГИЯ. МИР. МОСКВА. 2002 г. *
Birkett et al. A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of the Plasmodium falciparum Circumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts. INFECTION AND IMMUNITY, Dec. 2002, vol. 70, No. 12, p. 6860-6870. *
OLIVEIRA GA et al., Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adj uvant Montanide ISA 720 in a phase I trial, Infect. Immun., 2005, vol. 73, No. 6, pp. 3587-3597. *
RODRIGUEZ D et al., Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium, PLoS One, 2012.04.17, Vol. 7, No. 4, e34445, doi : 10. 1371/ journal. pone. 0034445. *
RODRIGUEZ D et al., Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium, PLoS One, 2012.04.17, Vol. 7, No. 4, e34445, doi : 10. 1371/ journal. pone. 0034445. OLIVEIRA GA et al., Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adj uvant Montanide ISA 720 in a phase I trial, Infect. Immun., 2005, vol. 73, No. 6, pp. 3587-3597. *
Б. ГЛИК. МОЛЕКУЛЯРНАЯ БИОТЕХНОЛОГИЯ. МИР. МОСКВА. 2002 г. *

Also Published As

Publication number Publication date
JP6734651B2 (ja) 2020-08-05
KR20160016856A (ko) 2016-02-15
AU2014275772B2 (en) 2020-01-02
BR112015030229B1 (pt) 2023-04-18
NZ714285A (en) 2021-02-26
EP3004348A1 (en) 2016-04-13
EP3004348B1 (en) 2023-03-08
MX386234B (es) 2025-03-18
SG10201709917VA (en) 2017-12-28
RU2015155821A3 (cg-RX-API-DMAC7.html) 2018-06-05
EP3004348A4 (en) 2016-08-03
US9512190B2 (en) 2016-12-06
WO2014196648A1 (en) 2014-12-11
KR20210116712A (ko) 2021-09-27
IL242656A (cg-RX-API-DMAC7.html) 2015-12-31
US20140363458A1 (en) 2014-12-11
CN105431535A (zh) 2016-03-23
US20190351041A1 (en) 2019-11-21
MX2015016627A (es) 2016-04-04
AU2014275772A1 (en) 2015-12-03
BR112015030229A2 (pt) 2017-08-22
CA2913832A1 (en) 2014-12-11
AP2015008926A0 (en) 2015-12-31
SG11201509614SA (en) 2015-12-30
ZA201508642B (en) 2022-03-30
KR102494564B1 (ko) 2023-01-31
TWI687442B (zh) 2020-03-11
BR112015030229A8 (pt) 2023-04-11
TW201529605A (zh) 2015-08-01
IL242656B (en) 2022-07-01
JP2016521539A (ja) 2016-07-25
CA2913832C (en) 2023-07-04
US20170035871A1 (en) 2017-02-09
RU2015155821A (ru) 2017-06-29

Similar Documents

Publication Publication Date Title
RU2702163C2 (ru) Вакцины против малярии
JP6824154B2 (ja) 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
Denis et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization
Jelínková et al. An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein
EP3666890A1 (en) Virus like particle comprising pd-1 antigen or pd-1 ligand antigen
US10385101B2 (en) Virus like particle comprising modified envelope protein E3
MX2014009916A (es) Composicion de particula tipo virus.
Wahl et al. How to induce protective humoral immunity against Plasmodium falciparum circumsporozoite protein
Kingston et al. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein
Nepal et al. Virus-like particle vaccines targeting a key epitope in circumsporozoite protein provide sterilizing immunity against malaria
EP3368068A1 (en) Virus like particle with efficient epitope display
US9943580B2 (en) Malaria vaccine
KR20200032169A (ko) 말라리아 백신
OA17590A (en) Malaria Vaccine
NZ714285B2 (en) Malaria vaccine
Pluschke et al. Development of a virosomal malaria vaccine candidate: from synthetic peptide design to clinical concept validation
Jelínková et al. An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein
JPWO2015133467A1 (ja) Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質

Legal Events

Date Code Title Description
PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20211005